Eirion Therapeutics' ET-02 flips a metabolic pathway in follicle cells, outperforming existing drugs in Phase 1 (N=24) with 2x hair density gains. Prevents greying too; Phase 2 (N=150) starts Q1 2026. Targets 80M US sufferers, with potential for prevention.